Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$9.15 USD
-0.13 (-1.40%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $9.13 -0.02 (-0.22%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Scholar Rock Holding Corporation [SRRK]
Reports for Purchase
Showing records 61 - 80 ( 134 total )
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Apitegromab Flexin Additional Endpoint Data at World Muscle Society
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
KOLs Highlight Key Bars For Success Ahead of DRAGON Update in 2H22; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
SAPPHIRE Aims to Shine as Bright as TOPAZ in SMA; Transferring Coverage With a Buy Rating and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Scholar Rock is Decoding TGF-a Signaling to Unlock its Untapped Therapeutic Power; Initiate at Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Apitegromab Leaves No Stone Unturned at MDA 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D